In the same month, Rita announced that the second phase research data of retatrutide was released at the annual meeting of ADA, showing that at 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) reached the main endpoint of efficacy evaluation for obese or overweight participants without diabetes, with an average weight loss of 17.5%
Beyond the Scale It is also worth noting that Retatrutide offers a host of hidden benefits
In addition, it is associated with less pain and fear of self-injection
Beso Wellness offers a complete toolkit for metabolic health: Tirzepatide (Dual Agonist) For patients who need more aggressive intervention, we may explore dual-action therapies that target both GLP-1 and GIP receptors
Glutathione IV therapy frequency is determined by the patients goals, lifestyle, and bodily reaction